Involvement of Transforming Growth Factor-β-Associated Kinase 1 in Fixed Airway Obstruction in Asthmatic Patients with Longer Disease Duration Independent on Airway Eosinophilia

OBJECTIVE: Transforming growth factor-β-associated kinase 1 (TAK1) mediates non-canonical TGF-β signalling by promoting adhesive, migratory, proliferative and contractile responses of fibroblasts to TGF-β(1).

However, TAK1 expression status in asthmatic patients with or without fixed airway obstruction (FAO) is unknown.

PATIENTS AND METHODS: A total of 60 adult asthmatics with FAO were recruited and compared to 43 those without FAO (nFAO).

TGF-β(1) concentrations, and total TAK1 and phosphorylated TAK1 (p-TAK1) levels were determined in sputum supernatants, cytospin, and whole cell lysate by ELISA, immunocytochemistry, and Western blot analysis, respectively, in asthmatics with and without FAO.

RESULTS: Asthmatic patients with FAO had much greater sputum TGF-β(1) concentrations than those without FAO.

This was independent of airway eosinophilia as there was no significant difference in TGF-β(1) levels between high and low eosinophil counts within FAO and nFAO groups.

In contrast, patients with FAO in the presence of sputum eosinophilia had greater expression of TAK1 and p-TAK1 than those without sputum eosinophilia (P=0.0032 and P=0.0061, respectively).

The Western Blot data of total TAK1 and p-TAK1 were consistent with the immunocytochemistry, showing upregulation in all sputum cell types (neutrophils, eosinophils, macrophages, lymphocytes and airway epithelial cells).

In addition, total TAK1 expression negatively correlated with pre- and post-bronchodilator FEV(1)/FVC ratio.

CONCLUSION: TAK1 may play a key role in asthmatic patients with fixed airway obstruction, which was independent of eosinophilic airway inflammation.

The interruption of TAK1 might have favourable clinical impact.